Small particle drug-eluting beads-transarterial chemoembolization combined with targeted therapy in the clinical treatment of unresectable liver cancer

Table 3 Comparison of liver function and tumor markers between the two groups before and after treatment

Indicator	Treatment period	Control group, n = 36	Joint group, n = 38	χ2/t	P value
ALT in U/L	Pre	39.41 ± 4.28	38.89 ± 4.55	0.506	0.615
	Post	45.12 ± 5.37	49.63 ± 5.18	3.677	0.001
AST in U/L	Pre	52.76 ± 8.33	53.02 ± 6.74	0.148	0.883
	Post	58.35 ± 6.92	65.71 ± 7.04	7.532	< 0.001
TBIL in μmol/L	Pre	20.01 ± 3.16	19.66 ± 2.25	0.551	0.583
	Post	25.41 ± 3.79	30.08 ± 4.11	5.073	< 0.001
ALB in g/L	Pre	37.85 ± 4.01	37.99 ± 3.32	0.164	0.870
	Post	32.66 ± 3.45	28.73 ± 2.99	5.245	< 0.001
AFP in μg/L	Pre	215.43 ± 20.77	218.96 ± 23.63	0.681	0.498
	Post	186.75 ± 15.46	114.65 ± 12.05	22.442	< 0.001

Data are mean ± standard deviation. AFP: Alpha fetoprotein; ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin.